United States · Markets & Finance · Morningstar

'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Published by Morningstar · United States 10 h ago

The Federal Trade Commission and seven states say Shkreli should be held in contempt Martin Shkreli was found guilty in 2017 of two counts of securities fraud and one count of…

Read the full article on Morningstar Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

NYT Business

Satlyt, founded by a former Google and SpaceX product manager, raises $8M to run AI on satellites

Decrypt

'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Share

Also worth reading

Police Identify 42-Year Old Man Killed at Six Flags Over Georgia

Google opens Gemini 4 Argon AI model to developers and businesses worldwide

The best Airbnb long-term rentals in 2026 — Marrakesh to Panama

Dangote Swings to $4.7 Billion Profit Ahead of Africa’s Biggest IPO

Satlyt, founded by a former Google and SpaceX product manager, raises $8M to run AI on satellites

Trezor Cuts Its Resellers After Ledger Finds Spy Implant in Crypto Wallets